Alnylam Pharmaceuticals, Inc. (ALNY) Investment Research Dashboard
About Alnylam Pharmaceuticals, Inc. (ALNY) stock analysis
Get live ALNY stock price $288.49, comprehensive Alnylam Pharmaceuticals, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ALNY stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline ...
Company Information
- CEO
- Yvonne L. Greenstreet
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2500
Contact Information
- Website
- https://www.alnylam.com
- Address
- 675 West Kendall Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 52.0)
✓ Lower volatility stock (Beta: 0.27) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Alnylam Pharmaceuticals, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Alnylam Pharmaceuticals, Inc.
- ⚠Investors should consider how Alnylam Pharmaceuticals, Inc. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 52.0) requires strong growth to justify
Market Cap
38.52B
P/E Ratio (TTM)
51.98
Beta
0.27
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare ALNY with peer companies:
- Price
- $872.67-1.76% (1D)
- Market cap
- 54.27B
- Price
- $165.74+4.33% (1D)
- Market cap
- 60.05B
- Price
- $233.09+1.67% (1D)
- Market cap
- 54.59B
- Price
- $303.44+4.27% (1D)
- Market cap
- 80.27B
- Price
- $320.25+2.94% (1D)
- Market cap
- 62.31B
- Price
- $83.32+0.37% (1D)
- Market cap
- 47.97B
- Price
- $568.86+2.28% (1D)
- Market cap
- 44.87B
- Price
- $693.42+3.98% (1D)
- Market cap
- 71.44B
- Price
- $201.34+3.54% (1D)
- Market cap
- 32.71B
- Price
- $77.50+0.74% (1D)
- Market cap
- 32.49B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
78/100 ⭐⭐⭐⭐⭐
- Overall
- +0.7%
- NYSE
- +0.6%
- NASDAQ
- +0.7%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +2.2% | +3.1% | +4.3% | 19.3 | 98/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.7% | +1.3% | +1.6% | 24.1 | 78/100⭐⭐⭐⭐⭐ |
| Communication Services | +1.4% | -0.7% | +2.9% | 22.2 | 74/100⭐⭐⭐⭐⭐ |
| Consumer Defensive | -0.2% | +1.8% | +0.7% | 29.7 | 64/100⭐⭐⭐⭐ |
| Basic Materials | +0.4% | +1.2% | -0.2% | 25.2 | 61/100⭐⭐⭐⭐ |
| Real Estate | -0.5% | +0.0% | -2.5% | 29.2 | 43/100⭐⭐⭐ |
| Energy | -2.1% | -3.7% | -4.1% | 19.1 | 39/100⭐⭐ |
| Utilities | -1.0% | +0.0% | -4.4% | 26.8 | 37/100⭐⭐ |
| Industrials | +0.6% | +0.4% | -9.9% | 30.1 | 23/100⭐ |
| Consumer Cyclical | +0.5% | -1.5% | -5.8% | 43.0 | 18/100⭐ |
| Technology | +0.6% | -1.6% | -7.2% | 40.7 | 15/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.